Wash. Judge Won't Stop Actos Generic For Mylan Appeal

Law360, New York (October 23, 2012, 9:47 PM EDT) -- Mylan Pharmaceuticals Inc. on Tuesday lost its bid to block Watson Laboratories Inc.'s production of a generic version of diabetes drug Actos while it appeals to the D.C. Circuit a Washington federal judge's Monday order directing the U.S. Food and Drug Administration to immediately approve the generic drug.

U.S. District Judge Amy Berman Jackson rejected Mylan's argument that it would be irreparably harmed by the entry into the market by Watson, which successfully challenged Mylan's market exclusivity for Actos granted by the FDA.

Mylan contended in...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

WATSON LABORATORIES, INC. v. SEBELIUS et al


Case Number

1:12-cv-01344

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Amy Berman Jackson

Date Filed

August 15, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.